Kintor Pharmaceutical Limited announced that the China phase II clinical trial of its in-house developed first-in-class androgen receptor proteolysis targeting chimera compound GT20029 tincture for the treatment of male androgenetic alopecia has reached the primary endpoint, with statistically significant and clinically meaningful results, as well as good safety and tolerability.
